Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from The United Laboratories International Holdings ( (HK:3933) ) is now available.
The United Laboratories International Holdings Limited announced that its product, Cefoperazone Sodium and Sulbactam Sodium for Injection, has passed the consistency evaluation by the China National Medical Products Administration. This approval enhances the company’s position in the anti-infective market and is expected to add value for shareholders as the company continues its research and development efforts.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in the production of antibiotics and other pharmaceutical products, with a strong emphasis on anti-infective medications.
Average Trading Volume: 13,479,448
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.68B
For an in-depth examination of 3933 stock, go to TipRanks’ Overview page.